

**A-G DERMATOLOGY REFERRAL FORM**

PATIENT INFORMATION				
Patient Name:		DOB:	Sex: <input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Other:	Weight: <input type="checkbox"/> lbs. <input type="checkbox"/> kg.
SSN:	Phone:	Allergies:		
Address:		City:	State:	Zip:
Emergency Contact:		Phone:	<input type="checkbox"/> Additional Information Attached	
PRESCRIBER INFORMATION				
Prescriber:		NPI:	DEA:	State Lic:
Supervising Physician:		Practice Name:		
Address:		City:	State:	Zip:
Phone:	Fax:	Key Office Contact:		Phone:
DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT				
<b>Primary Diagnosis:</b> <input type="checkbox"/> L28.1 Prurigo nodularis <input type="checkbox"/> L40.0 Psoriasis <input type="checkbox"/> L40.1; L40.2; L40.3, L40.4, L40.8, L40.54 Psoriatic arthritis <input type="checkbox"/> L40.59 <input type="checkbox"/> L50.1 Chronic Idiopathic Urticaria <input type="checkbox"/> L73.2 Hidradenitis Suppurativa <input type="checkbox"/> Other: _____				
Location: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Face <input type="checkbox"/> Scalp <input type="checkbox"/> Groin <input type="checkbox"/> Nails <input type="checkbox"/> Others: _____ Severity: <input type="checkbox"/> Mild (up to 3% BSA) <input type="checkbox"/> Moderate (3-10% BSA) <input type="checkbox"/> Severe (greater than 10% BSA), BSA _____ % If treated previously for this condition, please indicate which drugs have been tried and failed: _____ Date range of previous therapy: _____ <input type="checkbox"/> Is patient currently on therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Type/ medication(s): _____ <input type="checkbox"/> Will patient stop taking the above medication(s) before starting the new medication? <input type="checkbox"/> Yes <input type="checkbox"/> No, if yes, how long should patient wait before starting the new medication? _____ <input type="checkbox"/> Has patient received a PPD (tuberculosis) Skin Test? <input type="checkbox"/> Yes <input type="checkbox"/> No Results: _____ Prior to initiating treatment and periodically during therapy, patient should be evaluated for active tuberculosis and tested for latent infection.				
PRESCRIPTION INFORMATION				
<input type="checkbox"/> <b>STC Standard Protocol</b> will include the following: (1) dispensing ordered med/dose, (2) diluent to mix and/or dilute dose, (3) flushes to flush line and anakit med (epinephrine 0.3 mg IM / 0.15 mg IM (for pediatric patients) and diphenhydramine 50 mg/mL) and (4) premeds to take 30 mins before orally (Apap 325 mg, may repeat x1, and diphenhydramine 25 mg, may repeat x1).				
<b>Cibinco®</b> <input type="checkbox"/> 50mg tablet <input type="checkbox"/> 100mg tablet <input type="checkbox"/> 200mg tablet <input type="checkbox"/> 1 tablet po once daily <input type="checkbox"/> Other _____		QTY: <u>1 month</u>		Refills: _____
<b>Cimzia®</b> <input type="checkbox"/> 400 mg/mL SQ every 2 weeks <input type="checkbox"/> 400mg sq at weeks 0, 2, 4, then 200mg every other week thereafter (patient <=90kg)				
<b>Cosentyx®</b> <input type="checkbox"/> 150 mg/mL Sensoready® Pen <input type="checkbox"/> Prefilled Syringe 150 mg/mL <input type="checkbox"/> 150 mg Vial of Lyophilized powder <small>*Sensoready® pen will be dispensed if no preference indicated</small>		<input type="checkbox"/> Starter Dose: 300 mg SQ initially (Weeks 0, 1, 2, 3 and 4) then 300 mg SQ every 4 Weeks thereafter (Week 4) <input type="checkbox"/> Starter Dose not needed <input type="checkbox"/> Maintenance Dose: 300 mg SQ every 4 Weeks <input type="checkbox"/> Other _____		QTY: <u>5 weeks</u> QTY: <u>1 month</u> QTY: <u>1 month</u>
<b>Dupixent® (Dupilumab)</b> <input type="checkbox"/> 200 mg pen autoinjector <input type="checkbox"/> 200 mg prefilled syringe <input type="checkbox"/> 300 mg pen autoinjector <input type="checkbox"/> 300 mg prefilled syringe <small>*Pen will be dispensed if no preference indicated for adult dosing. Prefilled syringe may be used in ages ≥6 months. Prefilled pen is only for use in ages ≥2 years.</small>				
<b>Adults:</b> <input type="checkbox"/> Starter Dose: Inj. 600 mg SQ on Day 1, then 300 mg SQ every 2 Weeks starting on Day 15 <input type="checkbox"/> Starter Dose not needed <input type="checkbox"/> Maintenance Dose: Inj. 300 mg (1 syringe) SQ every 2 Weeks		QTY: <u>QS for starter</u> QTY: <u>1 month</u>		Refills: <u>0</u> Refills: _____
<b>Infants and Children ≥6 mo - &lt;6 yrs:</b> Initial loading dose not necessary in pediatric patients <6 yrs. <input type="checkbox"/> 5 to <15 kg: Dupixent 200mg SQ every 4 weeks <input type="checkbox"/> 15 to <30 kg: Dupixent 300 mg SQ every 4 weeks		QTY: <u>1 box of 2 pen/syr</u> Refills: _____		
<b>Children and Adolescents ≥6 years - ≤17 years:</b> <input type="checkbox"/> 15 to <30 kg: Initial: 600 mg SQ once (administered as two 300 mg injections), followed by maintenance dose of 300 mg every 4 weeks <input type="checkbox"/> 15 to <30 KG: maintenance: 300mg SQ every 4 weeks <input type="checkbox"/> 30 to <60 kg: Initial: 400 mg SQ once (administered as two 200 mg injections), followed by maintenance dose of 200 mg every other week <input type="checkbox"/> 30 to <60kg: maintenance: 200mg SQ every other week <input type="checkbox"/> ≥60 kg: Initial: 600 mg SQ once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week <input type="checkbox"/> ≥60kg: maintenance: 300mg SQ every other week		QTY: <u>1 box of 2 pen/syr</u> Refills: <u>0</u> QTY: <u>1 box of 2 pen/syr</u> Refills: _____ QTY: <u>1 box of 2 pen/syr</u> Refills: <u>0</u> QTY: <u>1 box of 2 pen/syr</u> Refills: _____ QTY: <u>1 box of 2 pen/syr</u> Refills: <u>0</u> QTY: <u>1 box of 2 pen/syr</u> Refills: _____		
<b>Enbrel®</b> <input type="checkbox"/> 50 mg/ml SureClick (autoinjector) <input type="checkbox"/> 50 mg Prefilled Syringe <input type="checkbox"/> Mini 50 mg Cartridge <small>*SureClick will be dispensed if no preference indicated</small>		<input type="checkbox"/> Enroll in Enliven® Program		
<input type="checkbox"/> Starter Dose: 50 mg SQ twice weekly (72-96 hours apart) for 3 months <input type="checkbox"/> Starter Dose not needed <input type="checkbox"/> Maintenance Dose: 50 mg SQ weekly <input type="checkbox"/> Other _____		QTY: <u>1 month</u> QTY: <u>1 month</u>		Refills: <u>2</u> Refills: _____
<b>Enbrel®</b> <input type="checkbox"/> 25 mg/0.5 mL Prefilled Syringe <input type="checkbox"/> 25 mg Single-Use Vial *Prefilled Syringe will be dispensed if no preference indicated <input type="checkbox"/> 25 mg SQ twice weekly (72-96 hours apart) <input type="checkbox"/> Other _____		QTY: <u>1 month</u> Refills: _____		
<b>Erivedge®</b> <input type="checkbox"/> 150 mg Capsules Take 1 Capsule Orally Once Daily		QTY: <u>28 capsules</u> Refills: _____		

**Prescriber's Signature:** \_\_\_\_\_  DAW (Dispense as Written) **Date:** \_\_\_\_\_

Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send electronic prescription or on official state prescription blank. Prescriber authorizes AcariaHealth to forward this prescription to another pharmacy, if needed.

**IMPORTANT NOTICE:** This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.